Adenoviruses are increasingly realised to be responsible for serious morbidity and mortality following allogeneic bone marrow transplantation. We describe a case of fulminant hepatic failure due to adenovirus serotype 2 in a 39-year-old woman who received a matched sibling allogeneic bone marrow transplant for multiply relapsed Hodgkin's disease. Isolated fulminant hepatic failure caused by this serotype of adenovirus has not previously been described. Keywords: adenovirus; hepatic failure; bone marrow transplant
mitted due to blood cytomegalovirus DNA polymerase chain reaction positivity and received ganciclovir. Several days afterwards she suffered an episode of respiratory failure, presumed to be Pneumocystis carinii pneumonia (despite nebulised pentamidine prophylaxis), which responded promptly to high-dose co-trimoxazole and methylprednisolone. The latter was discontinued before discharge on day 63. She remained fit and well for a further 5 months. At routine follow-up 6 months post allograft there was no evidence of Hodgkin's disease progression. Her CD4 count was, however, low at 150 × 10 6 /l with an abnormal CD4:CD8 ratio of 0.11. Her immunoglobulin levels were near normal: IgG 10.3 g/l, IgA 0.3 g/l and IgM 0.5 g/l. Renal and liver function tests were normal and haematological parameters were: Hb 114 g/l, TWCC 7.8 × 10 9 /l (neutrophils 2.5 × 10 9 /l), platelets 92 × 10 9 /l. On day 218 (7.5 months) post allograft she developed symptoms of coryza and fever, typical of a viral upper respiratory tract infection, which lasted for a week before settling. Her fever returned and persisted from day 233 and she subsequently developed progressive lethargy and weight loss. There were no other symptoms. She was admitted on day 255 and on examination was found to be febrile (39°C) but with no other clinical signs of note.
Blood tests showed a new leucopenia (3.5 × 10 9 /l; neutrophils 1.6 × 10 9 /l) and thrombocytopenia (25 × 10 9 /l). The haemoglobin was 110 g/l. Renal function remained normal but liver function tests had become abnormal: aspartate transaminase 423 IU/l (normal range 8-40 IU/l), alkaline phosphatase 909 IU/l (normal range 30-120 IU/l), bilirubin 19 mol/l and albumin 28 g/l. Clotting tests were normal. The erythrocyte sedimentation rate was 120 mm/h and the C reactive protein was 181 mg/l. No evidence of acute hepatitis caused by CMV, hepatitis A, B, C or HIV was found by serological or molecular methods. Repeated blood, urine and stool cultures were negative bacteriologically, as was marrow culture for Mycobacterium tuberculosis and M. avium intracellulare. Skin, oesophageal and gastric biopsies were normal with no evidence of graftversus-host disease. CT scanning of the thorax showed no evidence of disease recurrence.
Empirical treatment with broad-spectrum antibiotics and antifungals had no effect on her fever which continued unabated with spikes to 40.5°C. Her hepatic transaminitis also persisted to the same degree as on admission. There were no respiratory or urinary symptoms or signs and there was no diarrhoea. Her neutropenia and thrombocytopenia progressed although a bone marrow aspirate demonstrated active trilineage haemopoiesis, implying peripheral neutrophil and platelet consumption. On day 262 she became jaundiced (bilirubin 55 mol/l) and several days afterwards developed clinical signs of ascites. Ultrasound and magnetic resonance scans of the liver were abnormal with diffuse non-specific changes. A transjugular liver biopsy was performed which showed a small focus of lobular necrosis but no inflammation. Special stains for fungus and acidfast bacilli were negative, as were immunostains and polymerase chain reactions for Epstein-Barr virus, cytomegalovirus and herpes simplex virus types 1 and 2. Adenovirus immunostaining was not done. A portion of the biopsy was sent for viral and microbiological culture.
By day 278 total serum bilirubin had risen progressively to 380 mol/l with the transaminitis persisting unaltered. Encephalopathic symptoms had developed. On day 280, Epstein-Barr virus DNA was detected in both blood and ascitic fluid and therefore, in view of the strong possibility of an underlying viral aetiology for her progressive liver failure, she received donor lymphocytes (1 × 10 6 CD3 + cells/kg administered). Her condition, however, continued to deteriorate and she died of fulminant hepatic failure on day 286 post allograft. One week later the ante-mortem liver biopsy cultured adenovirus. This was found to be type 2 by specific neutralisation in tissue culture using antibodies obtained from PHLS Colindale (London, UK). Despite this there was no serological evidence of current adenovirus infection, as shown by the lack of any complement fixing antibodies in the serum at the time of admission (day 255), suggesting the possibility of a weak or absent immune response to a new infection.
Post-mortem liver biopsies showed extensive zones of necrosis with some autolytic changes in the adjacent viable liver parenchyma (Figure 1a ). There was no inflammatory reaction. Immunohistochemical staining showed strong granular positivity for adenovirus in necrotic zones, but not in viable hepatocytes (Figure 1b) . Immunostaining for latent membrane protein of Epstein-Barr virus, cytomegalovirus, herpes simplex types 1 and 2 and histochemical stains for fungi and acid-fast bacilli were all negative. Electron microscopy performed on paraffin-embedded material demonstrated small spheroidal particles in necrotic zones, the size (approximately 70 nm in diameter) and appearances of which were consistent with adenovirus ( Figure 2 ).
Discussion
Adenoviruses cause a variety of self-limiting, mainly respiratory, clinical syndromes in those with normal immune systems. In patients with primary and secondary immune deficiencies a different spectrum of more severe, often fatal, clinical syndromes is seen. 5 Following bone marrow transplantation adenovirus infections occur in 5-21% of patients. Although many have only minor symptoms, clinical manifestations include pneumonia, haemorrhagic cystitis, nephritis, gastritis, enterocolitis, encephalitis and disseminated disease and can result in significant morbidity and mortality. [6] [7] [8] Hepatitis has been reported as part of systemic adenovirus infections where other organs are more seriously affected. Serotypes isolated from liver under these circumstances include 1, 5, 29, 32 and 35.
6,7,9,10 Death due to iso-lated fulminant hepatic failure caused by adenovirus following bone marrow transplantation, as in our case, is rare and only three cases have previously been reported. In these cases death occurred within 100 days of the transplant, unlike in ours where the earliest symptoms did not appear until day 218. The underlying diagnoses and serotypes isolated in these cases were X-linked lymphoproliferative syndrome (serotype 5), 11 high-grade non-Hodgkin's lymphoma (serotype 5) 12 and acute lymphoblastic leukaemia (serotype 1). 7 In another case, a 22-year-old male with chronic granulocytic leukaemia in chronic phase, death occurred on day 150 from fulminant hepatic failure caused by adenovirus serotype 2, the same serotype as found in our patient. 13 This case is, however, distinguished from ours by the presence of prominent enterocolitic symptoms which contributed to death.
In our case there is circumstantial clinical and serological evidence that the viral infection that occurred may represent a new infection rather than reactivation of an old one. This emphasises that 8 months post allograft T cell-depleted bone marrow transplant patients remain considerably immunosuppressed, as is borne out in this case by the CD4 count of 150 × 10 6 /l and low CD4:CD8 ratio at routine follow-up 6 months post allograft, even though immunoglobulin levels were near normal.
Adenovirus infection should be considered in the differential diagnosis of hepatitis following allogeneic bone marrow transplantation. Although there is no reported effective treatment of adenovirus hepatitis, there are anecdotal reports of successful therapy of other adenovirus-associated conditions with intravenous ribavirin (nephritis 14 and haemorrhagic cystitis 15 ) and donor lymphocyte infusion (haemorrhagic cystitis 16 ). Furthermore, novel antiviral agents with activity against adenovirus are undergoing investigation and could be used on a compassionate basis (eg cidofovir, adefovir 17 ).
